Aktuellt
SENASTE
XVIVO delivers both improved Gross- and EBITDA margins and an overall organic growth of 42% (CER) which is very good by most comparisons. The Thoracic disposables buisness recorded sales below expectations in Q3 mostly as a result of the strong Q3 2022 and a strong Q2 in 2023. Thoracic gross margins improved by 4% to 85% in Q3. The outlook remains positive and the important US Heart study has started.
LÄS MER
